Metabolic precursors of nicotinamide adenine dinucleotide and the potential for their clinical use

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Nicotinamide adenine dinucleotide (NAD+) is present in all living cells and is a central signaling molecule and enzyme cofactor that is involved in many fundamental biological processes, including energy production, DNA repair, gene expression, and calcium-dependent signaling. It is known that NAD+ levels decrease in many pathological conditions, as well as with age in many tissues of rodents and humans, which contributes to the development of age-related pathology. There is evidence that an increase in intracellular NAD+ levels prevents the development of various pathological conditions. The review presents an analysis of modern data on the possibility of using precursors of NAD+ biosynthesis to provide the required level in body tissues in order to correct various disorders of vital functions.

About the authors

Iryna P. Sutsko

Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus

Author for correspondence.
Email: irynasutsko@gmail.com
ORCID iD: 0000-0001-9599-6944
SPIN-code: 3475-3276
Scopus Author ID: 55308045600

Cand. Sci. (Biol.), Senior Research Associate of the Laboratory of Biologically Active Substances

Belarus, Grodno

Alexey G. Shlyahtun

Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus

Email: a.shlyahtun@gmail.com
SPIN-code: 6134-9385

Head of the Laboratory of Biologically Active Substances

Belarus, Grodno

Igor N. Semenenya

Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus

Email: insemenenya@yandex.by

MD, Dr. Sci. (Med.), Professor, Director

Belarus, Grodno

References

  1. Nikiforov A, Kulikova V, Ziegler M. The human NAD metabolome: Functions, metabolism and compartmentalization. Crit Rev Biochem Mol Biol. 2015;50(4):284–297. doi: 10.3109/10409238.2015.1028612
  2. Kulikova VA, Gromyko DV, Nikiforov AA. The regulatory role of NAD in human and animal cells. Biochemistry (Moscow). 2018;83(7):800–812. doi: 10.1134/S0006297918070040
  3. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12–19. doi: 10.1016/j.tibs.2006.11.006
  4. Zhang N, Sauve AA. Regulatory effects of NAD+ metabolic pathways on sirtuin activity. Prog Mol Biol Transl Sci. 2018;154:71–104. doi: 10.1016/bs.pmbts.2017.11.012
  5. Fliegert R, Gasser A, Guse AH. Regulation of calcium signalling by adenine-based second messengers. Biochem Soc Trans. 2007;35(Pt 1):109–114. doi: 10.1042/BST0350109
  6. Cantó C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: A balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31–53. doi: 10.1016/j.cmet.2015.05.023
  7. Liu L, Su X, Quinn WJ III, et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 2018;27(5):1067–1080.e5. doi: 10.1016/j.cmet.2018.03.018
  8. Tannous C, Booz GW, Altara R, et al. Nicotinamide adenine dinucleotide: Biosynthesis, consumption and therapeutic role in cardiac diseases. Acta Physiol (Oxf). 2021;231(3):e13551. doi: 10.1111/apha.13551
  9. Gasperi V, Sibilano M, Savini I, Catani MV. Niacin in the central nervous system: An update of biological aspects and clinical applications. Int J Mol Sci. 2019;20(4):974. doi: 10.3390/ijms20040974
  10. Kulikova V, Shabalin K, Nerinovski K, et al. Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells. J Biol Chem. 2015;290(45):27124–27137. doi: 10.1074/jbc.M115.664458
  11. Katsyuba E, Auwerx J. Modulating NAD+ metabolism, from bench to bedside. EMBO J. 2017;36(18):2670–2683. doi: 10.15252/embj.201797135
  12. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–536. doi: 10.1016/j.cmet.2011.08.014
  13. Gomes AP, Price NL, Ling AJ, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. doi: 10.1016/j.cell.2013.11.037
  14. Clement J, Wong M, Poljak A, et al. The plasma NAD+ metabolome is dysregulated in “normal” aging. Rejuvenation Res. 2019;22(2):121–130. doi: 10.1089/rej.2018.2077
  15. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141. doi: 10.1038/s41580-020-00313-x
  16. Mukherjee S, Chellappa K, Moffitt A, et al. Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration. Hepatology. 2017;65(2):616–663. doi: 10.1002/hep.28912
  17. Cantó C, Houtkooper RH, Pirinen E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838–847. doi: 10.1016/j.cmet.2012.04.022
  18. Braidy N, Berg J, Clement J, et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: Rationale, biochemistry, pharmacokinetics, and outcomes. Antioxid Redox Signal. 2019;30(2):251–294. doi: 10.1089/ars.2017.7269
  19. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117(4):495–550. doi: 10.1016/s0092-8674(04)00416-7
  20. Trammell SA, Yu L, Redpath P, et al. Nicotinamide riboside is a major NAD+ precursor vitamin in cow milk. J Nutr. 2016;146(5):957–963. doi: 10.3945/jn.116.230078
  21. Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. doi: 10.1038/ncomms12948
  22. Kropotov A, Kulikova V, Nerinovski K, et al. Equilibrative nucleoside transporters mediate the import of nicotinamide riboside and nicotinic acid riboside into human cells. Int J Mol Sci. 2021;22(3):1391. doi: 10.3390/ijms22031391
  23. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–528. doi: 10.1016/j.cmet.2017.11.002
  24. Gong B, Pan Y, Vempati P, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol Aging. 2013;34(6):1581–1588. doi: 10.1016/j.neurobiolaging.2012.12.005
  25. Schöndorf DC, Ivanyuk D, Baden P, et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s disease. Cell Rep. 2018;23(10):2976–2988. doi: 10.1016/j.celrep.2018.05.009
  26. Lloret A, Beal MF. PGC-1α, sirtuins and PARPs in Huntington’s disease and other neurodegenerative conditions: NAD+ to rule them all. Neurochem Res. 2019;44(10):2423–2434. doi: 10.1007/s11064-019-02809-1
  27. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717–1728.e6. doi: 10.1016/j.celrep.2019.07.043
  28. Brown KD, Maqsood S, Huang JY, et al. Activation of SIRT3 by the NAD⁺ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 2014;20(6):1059–1068. doi: 10.1016/j.cmet.2014.11.003
  29. Khan NA, Auranen M, Paetau I, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med. 2014;6(6):721–731. doi: 10.1002/emmm.201403943
  30. Trammell SA, Weidemann BJ, Chadda A, et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci Rep. 2016;6:26933. doi: 10.1038/srep26933
  31. Zhou CC, Yang X, Hua X, et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016;173(15):2352–2368. doi: 10.1111/bph.13513
  32. Tummala KS, Gomes AL, Yilmaz M, et al. Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer Cell. 2014;26(6):826–839. doi: 10.1016/j.ccell.2014.10.002
  33. Diguet N, Trammell SAJ, Tannous C, et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation. 2018;137(21):2256–2273. doi: 10.1161/CIRCULATIONAHA.116.026099
  34. Frederick DW, Loro E, Liu L, et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. Cell Metab. 2016;24(2):269–282. doi: 10.1016/j.cmet.2016.07.005
  35. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi: 10.1038/s41467-018-03421-7
  36. Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459. doi: 10.1371/journal.pone.0186459
  37. Chi Y, Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care. 2013;16(6):657–666. doi: 10.1097/MCO.0b013e32836510c0
  38. Effects of nicotinamide riboside on the clinical outcome of Covid-19 in the elderly [Internet]. ClinicalTrials.gov Identifier: NCT04407390; 2021 Nov 5. Available from: https://clinicaltrials.gov/ct2/show/NCT04407390. Accessed: 21.09.2022.
  39. Poddar SK, Sifat AE, Haque S, et al. Nicotinamide mononucleotide: Exploration of diverse therapeutic applications of a potential molecule. Biomolecules. 2019;9(1):34. doi: 10.3390/biom9010034
  40. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795–806. doi: 10.1016/j.cmet.2016.09.013
  41. De Picciotto NE, Gano LB, Johnson LC, et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016;15(3):522–530. doi: 10.1111/acel.12461
  42. Guan Y, Wang SR, Huang XZ, et al. Nicotinamide mononucleotide, an NAD+ precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. J Am Soc Nephrol. 2017;28(8):2337–2352. doi: 10.1681/ASN.2016040385
  43. Stromsdorfer KL, Yamaguchi S, Yoon MJ, et al. NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 2016;16(7):1851–1860. doi: 10.1016/j.celrep.2016.07.027
  44. Ratajczak J, Joffraud M, Trammell SA, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:13103. doi: 10.1038/ncomms13103
  45. Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47–57. doi: 10.1038/s42255-018-0009-4
  46. Martin AS, Abraham DM, Hershberger KA, et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model. JCI Insight. 2017;2(14):e93885. doi: 10.1172/jci.insight.93885
  47. Park JH, Long A, Owens K, Kristian T. Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia. Neurobiol Dis. 2016;95:102–110. doi: 10.1016/j.nbd.2016.07.018
  48. Wang X, Hu X, Yang Y, et al. Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 2016;1643:1–9. doi: 10.1016/j.brainres.2016.04.060
  49. Yao Z, Yang W, Gao Z, Jia P. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci Lett. 2017;647:133–140. doi: 10.1016/j.neulet.2017.03.027
  50. Assiri MA, Ali HR, Marentette JO, et al. Investigating RNA expression profiles altered by nicotinamide mononucleotide therapy in a chronic model of alcoholic liver disease. Hum Genomics. 2019;13(1):6. doi: 10.1186/s40246-019-0251-1
  51. Lin JB, Kubota S, Ban N, et al. NAMPT-mediated NAD(+) biosynthesis is essential for vision in mice. Cell Rep. 2016;17(1):69–85. doi: 10.1016/j.celrep.2016.08.073
  52. Klimova N, Long A, Kristian T. Nicotinamide mononucleotide alters mitochondrial dynamics by SIRT3-dependent mechanism in male mice. J Neurosci Res. 2019;97(8):975–990. doi: 10.1002/jnr.24397
  53. Hacioglu C, Kar F, Kanbak G. Reproductive effects of nicotinamide on testicular function and structure in old male rats: Oxidative, apoptotic, hormonal, and morphological analyses. Reprod Sci. 2021;28(12):3352–3360. doi: 10.1007/s43032-021-00647-7
  54. Kiss T, Balasubramanian P, Valcarcel-Ares MN, et al. Nicotinamide mononucleotide (NMN) treatment attenuates oxidative stress and rescues angiogenic capacity in aged cerebromicrovascular endothelial cells: a potential mechanism for the prevention of vascular cognitive impairment. Geroscience. 2019;41(5):619–630. doi: 10.1007/s11357-019-00074-2
  55. Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54. doi: 10.1186/s12970-021-00442-4
  56. Das A, Huang GX, Bonkowski MS, et al. Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging. Cell. 2019;176(4):944–945. doi: 10.1016/j.cell.2019.01.026
  57. Eldridge AL. Comparison of 1989 RDAs and DRIs for water-soluble vitamins. Nutr Today. 2004;39(2):88–93. doi: 10.1097/00017285-200403000-00011
  58. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18(4):415–442. doi: 10.1097/MOL.0b013e3282364add
  59. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009;63(9):1369–1377. doi: 10.1111/j.1742-1241.2009.02099.x
  60. Titcomb TJ, Tanumihardjo SA. Global concerns with B vitamin statuses: Biofortification, fortification, hidden hunger, interactions, and toxicity. Compr Rev Food Sci Food Saf. 2019;18(6):1968–1984. doi: 10.1111/1541-4337.12491
  61. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–50763. doi: 10.1074/jbc.M408388200
  62. Stein LR, Imai S. Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 2014;33(12):1321–1340. doi: 10.1002/embj.201386917
  63. Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: Mechanisms and safety assessment. Biomolecules. 2020;10(5):687. doi: 10.3390/biom10050687
  64. Fania L, Mazzanti C, Campione E, et al. Role of nicotinamide in genomic stability and skin cancer chemoprevention. Int J Mol Sci. 2019;20(23):5946. doi: 10.3390/ijms20235946
  65. Agote M, Viaggi M, Kreimann E, et al. Influence of nicotinamide on the radiosensitivity of normal and goitrous thyroid in the rat. Thyroid. 2001;11(11):1003–1007. doi: 10.1089/105072501753271671
  66. Malesu R, Martin AJ, Lyons JG, et al. Nicotinamide for skin cancer chemoprevention: Effects of nicotinamide on melanoma in vitro and in vivo. Photochem Photobiol Sci. 2020;19(2):171–179. doi: 10.1039/c9pp00388f
  67. Scatozza F, Moschella F, D’Arcangelo D, et al. Nicotinamide inhibits melanoma in vitro and in vivo. J Exp Clin Cancer Res. 2020;39(1):211. doi: 10.1186/s13046-020-01719-3
  68. Takahashi N, Li F, Fushima T, et al. Vitamin B3 nicotinamide: A promising candidate for treating preeclampsia and improving fetal growth. Tohoku J Exp Med. 2018;244(3):243–248. doi: 10.1620/tjem.244.243
  69. Forbat E, Al-Niaimi F, Ali FR. Use of nicotinamide in dermatology. Clin Exp Dermatol. 2017;42(2):137–144. doi: 10.1111/ced.13021
  70. Ito TK, TomohitoSato T, Hakamata A, et al. A nonrandomized study of single oral supplementation within the daily tolerable upper level of nicotinamide affects blood nicotinamide and NAD+ levels in healthy subjects. Transl Med Aging. 2020;4:45–54. doi: 10.1016/j.tma.2020.04.002
  71. Ranchoff RE, Tomecki KJ. Niacin or niacinamide? Nicotinic acid or nicotinamide? What is the difference? J Am Acad Dermatol. 1986;15(1):116–117. doi: 10.1016/s0190-9622(86)80149-9
  72. Connell NJ, Houtkooper RH, Schrauwen P. NAD+ metabolism as a target for metabolic health: Have we found the silver bullet? Diabetologia. 2019;62(6):888–899. doi: 10.1007/s00125-019-4831-3
  73. Roberti A, Fernández AF, Fraga MF. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Mol Metab. 2021;45:101165. doi: 10.1016/j.molmet.2021.101165

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Eco-Vector



Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».